| 词条 | Asset-Centricity |
| 释义 |
The asset-centric investing model is an attempt to streamline the drug discovery process, based on the widely held belief that it has become too expensive.[2][4] It de-couples life sciences assets from the infrastructure necessary to develop them, with the goal of improving returns on invested capital.[5] A typical asset-centric startup company would have a single asset, or sometimes two, with a team of experts, including drug developers, shared across a back-end structure and across a variety of portfolio life sciences companies. These team members would coalesce for specific, focused drug-discovery projects[2] The bulk of funding would support the development of the primary asset, with the rest supporting a secondary asset and infrastructure.[1][5][6][7] HistoryThe asset-centric model of investing was developed by Index Ventures, a venture capital firm.[7][8] Forms of the asset-centric model have subsequently been adopted by other life sciences investment firms such as Atlas Venture and Symphony Capital.[2] Examples of Asset-Centric companiesExamples of life sciences companies built on the asset-centric investing model include:
References1. ^1 {{cite news |title= Decentralising drug research |url= https://www.economist.com/news/business/21602689-why-row-over-giant-drug-company-takeovers-misses-point-pharmed-out|work= The Economist|date= May 24, 2014}} 2. ^1 2 3 4 5 6 {{cite news |title= Venture capitalists ride biotech wave one drug at a time |url= https://www.reuters.com/article/biotech-funding-idUSL6N0WT3XX20150410|work= Reuters|date= April 10, 2015}} 3. ^{{cite news |title=Atlas Venture unveils a $280M pure play biotech startup fund |url=http://www.fiercebiotech.com/story/atlas-venture-unveils-280m-biotech-startup-fund/2015-04-17|work= FierceBiotech|date= April 17, 2015}} 4. ^{{cite news |title= Why drugs are expensive: It’s the science, stupid.|url= http://blogs.scientificamerican.com/the-curious-wavefunction/why-drugs-are-expensive-ite28099s-the-science-stupid/|work= Scientific American|date= January 6, 2014}} 5. ^1 {{cite news |title= The Lone Biotech Bear? |url= https://www.forbes.com/sites/davidgrainger/2015/01/21/the-lone-biotech-bear/#3f8437b26563|work= Forbes |date= January 21, 2015}} 6. ^{{cite news |title= Glaxo Joins J&J in $200 Million Fund With Index Ventures |url= https://www.bloomberg.com/news/articles/2012-03-21/glaxo-joins-j-j-in-200-million-fund-with-index-ventures |work= Bloomberg News |date= March 21, 2012}} 7. ^1 {{cite news |title= Index Ventures adds big pharma to asset-centric model |url= http://www.epvantage.com/Universal/View.aspx?type=Story&id=283887&isEPVantage=yes |work= EPVantage |date= March 21, 2012}} 8. ^{{cite news |title= Index Ventures appoints antibody expert as partner |url=http://www.mednous.com/appointment/index-ventures-appoints-antibody-expert-partner|work= MedNous|date= September 3, 2010}} 9. ^{{cite news |title= Lilly buys back a migraine therapy from Arteaus Therapeutics|url= http://www.fiercebiotech.com/story/lilly-buys-back-migraine-therapy-arteaus-therapeutics/2014-01-13|work= FierceBiotech|date= January 13, 2014}} 10. ^{{cite news |title= Asset-Centric Milestone |url= http://www.biocentury.com/biotech-pharma-news/finance/2014-01-20/lilly-arteaus-deal-provides-atlas-venture-with-first-asset-centric-graduation-a13 |work= BioCentury |date= January 20, 2014}} 11. ^{{cite news |title= J&J stays mum about cash, but biotech buyout is a landmark win for Index fund|url= http://www.fiercebiotech.com/story/lilly-buys-back-migraine-therapy-arteaus-therapeutics/2014-01-13|work= FierceBiotech|date= March 18, 2015}} 1 : Finance theories |
| 随便看 |
开放百科全书收录14589846条英语、德语、日语等多语种百科知识，基本涵盖了大多数领域的百科知识，是一部内容自由、开放的电子版国际百科全书。